# Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
Canonical URL: https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-doses-first-patient-in-phase-1b-2-trial-of-piktor-in-hr-her2-advanced-breast-cancer
Ticker: SNSE
Company: Sensei Biotherapeutics
Source: Sensei Biotherapeutics
Published: 2026-05-05 11:30 EST
Original Source URL: https://investors.senseibio.com
## Summary

PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open BOSTON --(BUSINESS WIRE)--May 5, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that

## Article Body
PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open BOSTON --(BUSINESS WIRE)--May 5, 2026-- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that
## Recent Company News
- 2026-05-15 11:30 EST — [Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Sensei Biotherapeutics
- 2026-05-05 11:30 EST — [Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-doses-first-patient-in-phase-1b-2-trial-of-piktor-in-hr-her2-advanced-breast-cancer) — Source: Sensei Biotherapeutics
- 2026-04-09 11:30 EST — [Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Sensei Biotherapeutics
- 2026-03-30 11:30 EST — [Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-full-year-2025-financial-results-and-provides-corporate-update) — Source: Sensei Biotherapeutics
- 2026-03-17 10:00 EST — [Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Sensei Biotherapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)